Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

XXXiaojing Xing

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows a complete response rate of 80% in high-risk follicular lymphoma patients receiving zanubrutinib therapy, indicating promising outcomes.

Key Points

  • Assess efficacy and safety of zanubrutinib with anti-CD20 monoclonal antibodies in high-risk follicular and marginal zone lymphoma patients.
  • Retrospective analysis of high-risk patients receiving zanubrutinib with anti-CD20 therapy.
  • Inclusion of treatment-naïve patients with FL and MZL from 2022 to 2025.
  • Evaluated objective response rate and complete response rates after treatment cycles.
  • Objective response rate of 93.3% after 6 cycles, complete response rate of 80%.
  • No deaths or disease progression in 18 months follow-up.
  • Hematologic toxicity was the most common adverse event noted.

Cite This Study

Xiaojing Xing (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d203https://doi.org/10.1182/blood-2025-7107
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study2025
  2. 2Efficacy and safety of zanubrutinib combination therapy and monotherapy maintenance in patients with follicular lymphoma: A retrospective single-center analysis2025
  3. 3Efficacy and safety of zanubrutinib combined with chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma2025
  4. 4Efficacy and safety of zanubrutinib-containing regimens in patients with newly diagnosed Mantle Cell Lymphoma: Interim results from a Phase II investigator-initiated study2025
  5. 5Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma2025